ArticleOncotarget2016

MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.

Yihui Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.